Review



rho activator i  (Cytoskeleton Inc)


Bioz Verified Symbol Cytoskeleton Inc is a verified supplier
Bioz Manufacturer Symbol Cytoskeleton Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Cytoskeleton Inc rho activator i
    Rho Activator I, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 69 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rho activator i/product/Cytoskeleton Inc
    Average 95 stars, based on 69 article reviews
    rho activator i - by Bioz Stars, 2026-03
    95/100 stars

    Images



    Similar Products

    rho activator i  (Cytoskeleton Inc)
    95
    Cytoskeleton Inc rho activator i
    Rho Activator I, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rho activator i/product/Cytoskeleton Inc
    Average 95 stars, based on 1 article reviews
    rho activator i - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    rhoa activator ii  (Cytoskeleton Inc)
    97
    Cytoskeleton Inc rhoa activator ii
    (A) Schematic of the proposed signaling pathway showing ADGRG1 activating the <t>RhoA</t> pathway to promote F-actin polymerization in preOLs. (B) Immunostaining of control and cKO preOLs for ADGRG1 (H11, green), GTP-RhoA (magenta), DAPI (blue) and brightfield. Colocalization between ADGRG1 and GTP-RhoA was observed in the processes of control preOLs, but both signals were downregulated in cKO preOLs. Scale bar, 10 μm. (C) Representative images of control and cKO oligodendrocyte cultures differentiated for 3, 5, or 7 days, treated with either vehicle, Rho inhibitor (for control), or <t>Rho</t> <t>activator</t> (for cKO). Cultures were stained for MBP (magenta), BCAS1 (green), Olig2 (gray), and DAPI (blue). Scale bar, 10 μm. (D) Quantification of the percentage of BCAS1 + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. ** p=0.0011 (diff 3 day Con vs cKO), ** p=0.0011 (diff 3 day cKO vs cKO + Rho activator), ** p=0.0088 (diff 5 day Con vs Con + Rho inhibitor), * p=0.0103 (diff 5 day Con vs cKO), * p=0.0181 (diff 5 day cKO vs cKO + Rho activator), *** p=0.0005 (diff 7 day Con vs cKO), *** p=0.0003 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. (E) Quantification of the percentage of MBP + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. **** p<0.0001 (diff 5 day Con vs Con + Rho inhibitor), ** p=0.0047 (diff 5 day Con vs cKO), * p=0.0108 (diff 5 day cKO vs cKO + Rho activator), **** p<0.0001 (diff 7 day Con vs Con + Rho inhibitor), ** p=0.0010 (diff 7 day Con vs cKO), **** p<0.0001 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. Data are presented as means ± SEM.
    Rhoa Activator Ii, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rhoa activator ii/product/Cytoskeleton Inc
    Average 97 stars, based on 1 article reviews
    rhoa activator ii - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    rho gtpase activity  (Cytoskeleton Inc)
    95
    Cytoskeleton Inc rho gtpase activity
    (A) Schematic of the proposed signaling pathway showing ADGRG1 activating the <t>RhoA</t> pathway to promote F-actin polymerization in preOLs. (B) Immunostaining of control and cKO preOLs for ADGRG1 (H11, green), GTP-RhoA (magenta), DAPI (blue) and brightfield. Colocalization between ADGRG1 and GTP-RhoA was observed in the processes of control preOLs, but both signals were downregulated in cKO preOLs. Scale bar, 10 μm. (C) Representative images of control and cKO oligodendrocyte cultures differentiated for 3, 5, or 7 days, treated with either vehicle, Rho inhibitor (for control), or <t>Rho</t> <t>activator</t> (for cKO). Cultures were stained for MBP (magenta), BCAS1 (green), Olig2 (gray), and DAPI (blue). Scale bar, 10 μm. (D) Quantification of the percentage of BCAS1 + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. ** p=0.0011 (diff 3 day Con vs cKO), ** p=0.0011 (diff 3 day cKO vs cKO + Rho activator), ** p=0.0088 (diff 5 day Con vs Con + Rho inhibitor), * p=0.0103 (diff 5 day Con vs cKO), * p=0.0181 (diff 5 day cKO vs cKO + Rho activator), *** p=0.0005 (diff 7 day Con vs cKO), *** p=0.0003 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. (E) Quantification of the percentage of MBP + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. **** p<0.0001 (diff 5 day Con vs Con + Rho inhibitor), ** p=0.0047 (diff 5 day Con vs cKO), * p=0.0108 (diff 5 day cKO vs cKO + Rho activator), **** p<0.0001 (diff 7 day Con vs Con + Rho inhibitor), ** p=0.0010 (diff 7 day Con vs cKO), **** p<0.0001 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. Data are presented as means ± SEM.
    Rho Gtpase Activity, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rho gtpase activity/product/Cytoskeleton Inc
    Average 95 stars, based on 1 article reviews
    rho gtpase activity - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    rho rac cdc42 activator i  (Cytoskeleton Inc)
    95
    Cytoskeleton Inc rho rac cdc42 activator i
    (A) Schematic of the proposed signaling pathway showing ADGRG1 activating the <t>RhoA</t> pathway to promote F-actin polymerization in preOLs. (B) Immunostaining of control and cKO preOLs for ADGRG1 (H11, green), GTP-RhoA (magenta), DAPI (blue) and brightfield. Colocalization between ADGRG1 and GTP-RhoA was observed in the processes of control preOLs, but both signals were downregulated in cKO preOLs. Scale bar, 10 μm. (C) Representative images of control and cKO oligodendrocyte cultures differentiated for 3, 5, or 7 days, treated with either vehicle, Rho inhibitor (for control), or <t>Rho</t> <t>activator</t> (for cKO). Cultures were stained for MBP (magenta), BCAS1 (green), Olig2 (gray), and DAPI (blue). Scale bar, 10 μm. (D) Quantification of the percentage of BCAS1 + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. ** p=0.0011 (diff 3 day Con vs cKO), ** p=0.0011 (diff 3 day cKO vs cKO + Rho activator), ** p=0.0088 (diff 5 day Con vs Con + Rho inhibitor), * p=0.0103 (diff 5 day Con vs cKO), * p=0.0181 (diff 5 day cKO vs cKO + Rho activator), *** p=0.0005 (diff 7 day Con vs cKO), *** p=0.0003 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. (E) Quantification of the percentage of MBP + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. **** p<0.0001 (diff 5 day Con vs Con + Rho inhibitor), ** p=0.0047 (diff 5 day Con vs cKO), * p=0.0108 (diff 5 day cKO vs cKO + Rho activator), **** p<0.0001 (diff 7 day Con vs Con + Rho inhibitor), ** p=0.0010 (diff 7 day Con vs cKO), **** p<0.0001 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. Data are presented as means ± SEM.
    Rho Rac Cdc42 Activator I, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rho rac cdc42 activator i/product/Cytoskeleton Inc
    Average 95 stars, based on 1 article reviews
    rho rac cdc42 activator i - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    rho activation assay biochem kit  (Cytoskeleton Inc)
    97
    Cytoskeleton Inc rho activation assay biochem kit
    (A) Schematic of the proposed signaling pathway showing ADGRG1 activating the <t>RhoA</t> pathway to promote F-actin polymerization in preOLs. (B) Immunostaining of control and cKO preOLs for ADGRG1 (H11, green), GTP-RhoA (magenta), DAPI (blue) and brightfield. Colocalization between ADGRG1 and GTP-RhoA was observed in the processes of control preOLs, but both signals were downregulated in cKO preOLs. Scale bar, 10 μm. (C) Representative images of control and cKO oligodendrocyte cultures differentiated for 3, 5, or 7 days, treated with either vehicle, Rho inhibitor (for control), or <t>Rho</t> <t>activator</t> (for cKO). Cultures were stained for MBP (magenta), BCAS1 (green), Olig2 (gray), and DAPI (blue). Scale bar, 10 μm. (D) Quantification of the percentage of BCAS1 + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. ** p=0.0011 (diff 3 day Con vs cKO), ** p=0.0011 (diff 3 day cKO vs cKO + Rho activator), ** p=0.0088 (diff 5 day Con vs Con + Rho inhibitor), * p=0.0103 (diff 5 day Con vs cKO), * p=0.0181 (diff 5 day cKO vs cKO + Rho activator), *** p=0.0005 (diff 7 day Con vs cKO), *** p=0.0003 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. (E) Quantification of the percentage of MBP + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. **** p<0.0001 (diff 5 day Con vs Con + Rho inhibitor), ** p=0.0047 (diff 5 day Con vs cKO), * p=0.0108 (diff 5 day cKO vs cKO + Rho activator), **** p<0.0001 (diff 7 day Con vs Con + Rho inhibitor), ** p=0.0010 (diff 7 day Con vs cKO), **** p<0.0001 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. Data are presented as means ± SEM.
    Rho Activation Assay Biochem Kit, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rho activation assay biochem kit/product/Cytoskeleton Inc
    Average 97 stars, based on 1 article reviews
    rho activation assay biochem kit - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    rhoa activator  (Cytoskeleton Inc)
    97
    Cytoskeleton Inc rhoa activator
    (A) Schematic of the proposed signaling pathway showing ADGRG1 activating the <t>RhoA</t> pathway to promote F-actin polymerization in preOLs. (B) Immunostaining of control and cKO preOLs for ADGRG1 (H11, green), GTP-RhoA (magenta), DAPI (blue) and brightfield. Colocalization between ADGRG1 and GTP-RhoA was observed in the processes of control preOLs, but both signals were downregulated in cKO preOLs. Scale bar, 10 μm. (C) Representative images of control and cKO oligodendrocyte cultures differentiated for 3, 5, or 7 days, treated with either vehicle, Rho inhibitor (for control), or <t>Rho</t> <t>activator</t> (for cKO). Cultures were stained for MBP (magenta), BCAS1 (green), Olig2 (gray), and DAPI (blue). Scale bar, 10 μm. (D) Quantification of the percentage of BCAS1 + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. ** p=0.0011 (diff 3 day Con vs cKO), ** p=0.0011 (diff 3 day cKO vs cKO + Rho activator), ** p=0.0088 (diff 5 day Con vs Con + Rho inhibitor), * p=0.0103 (diff 5 day Con vs cKO), * p=0.0181 (diff 5 day cKO vs cKO + Rho activator), *** p=0.0005 (diff 7 day Con vs cKO), *** p=0.0003 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. (E) Quantification of the percentage of MBP + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. **** p<0.0001 (diff 5 day Con vs Con + Rho inhibitor), ** p=0.0047 (diff 5 day Con vs cKO), * p=0.0108 (diff 5 day cKO vs cKO + Rho activator), **** p<0.0001 (diff 7 day Con vs Con + Rho inhibitor), ** p=0.0010 (diff 7 day Con vs cKO), **** p<0.0001 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. Data are presented as means ± SEM.
    Rhoa Activator, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rhoa activator/product/Cytoskeleton Inc
    Average 97 stars, based on 1 article reviews
    rhoa activator - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic of the proposed signaling pathway showing ADGRG1 activating the RhoA pathway to promote F-actin polymerization in preOLs. (B) Immunostaining of control and cKO preOLs for ADGRG1 (H11, green), GTP-RhoA (magenta), DAPI (blue) and brightfield. Colocalization between ADGRG1 and GTP-RhoA was observed in the processes of control preOLs, but both signals were downregulated in cKO preOLs. Scale bar, 10 μm. (C) Representative images of control and cKO oligodendrocyte cultures differentiated for 3, 5, or 7 days, treated with either vehicle, Rho inhibitor (for control), or Rho activator (for cKO). Cultures were stained for MBP (magenta), BCAS1 (green), Olig2 (gray), and DAPI (blue). Scale bar, 10 μm. (D) Quantification of the percentage of BCAS1 + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. ** p=0.0011 (diff 3 day Con vs cKO), ** p=0.0011 (diff 3 day cKO vs cKO + Rho activator), ** p=0.0088 (diff 5 day Con vs Con + Rho inhibitor), * p=0.0103 (diff 5 day Con vs cKO), * p=0.0181 (diff 5 day cKO vs cKO + Rho activator), *** p=0.0005 (diff 7 day Con vs cKO), *** p=0.0003 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. (E) Quantification of the percentage of MBP + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. **** p<0.0001 (diff 5 day Con vs Con + Rho inhibitor), ** p=0.0047 (diff 5 day Con vs cKO), * p=0.0108 (diff 5 day cKO vs cKO + Rho activator), **** p<0.0001 (diff 7 day Con vs Con + Rho inhibitor), ** p=0.0010 (diff 7 day Con vs cKO), **** p<0.0001 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. Data are presented as means ± SEM.

    Journal: bioRxiv

    Article Title: Pre-myelinating oligodendrocyte ADGRG1 is required for axon ensheathment and CNS myelin formation

    doi: 10.64898/2026.01.26.701898

    Figure Lengend Snippet: (A) Schematic of the proposed signaling pathway showing ADGRG1 activating the RhoA pathway to promote F-actin polymerization in preOLs. (B) Immunostaining of control and cKO preOLs for ADGRG1 (H11, green), GTP-RhoA (magenta), DAPI (blue) and brightfield. Colocalization between ADGRG1 and GTP-RhoA was observed in the processes of control preOLs, but both signals were downregulated in cKO preOLs. Scale bar, 10 μm. (C) Representative images of control and cKO oligodendrocyte cultures differentiated for 3, 5, or 7 days, treated with either vehicle, Rho inhibitor (for control), or Rho activator (for cKO). Cultures were stained for MBP (magenta), BCAS1 (green), Olig2 (gray), and DAPI (blue). Scale bar, 10 μm. (D) Quantification of the percentage of BCAS1 + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. ** p=0.0011 (diff 3 day Con vs cKO), ** p=0.0011 (diff 3 day cKO vs cKO + Rho activator), ** p=0.0088 (diff 5 day Con vs Con + Rho inhibitor), * p=0.0103 (diff 5 day Con vs cKO), * p=0.0181 (diff 5 day cKO vs cKO + Rho activator), *** p=0.0005 (diff 7 day Con vs cKO), *** p=0.0003 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. (E) Quantification of the percentage of MBP + Olig2 + cells in total Olig2 + cells across differentiation time points. Each circle represents one biological replicate. **** p<0.0001 (diff 5 day Con vs Con + Rho inhibitor), ** p=0.0047 (diff 5 day Con vs cKO), * p=0.0108 (diff 5 day cKO vs cKO + Rho activator), **** p<0.0001 (diff 7 day Con vs Con + Rho inhibitor), ** p=0.0010 (diff 7 day Con vs cKO), **** p<0.0001 (diff 7 day cKO vs cKO + Rho activator). Two-way ANOVA with Bonferroni’s multiple comparisons test. Data are presented as means ± SEM.

    Article Snippet: The following compounds were used: RhoA Activator II (1 μg/mL, Cytoskeleton Inc., Cat. #: CN03-A) and RhoA Inhibitor I (1 μg/mL, Cytoskeleton Inc., Cat. #: CT04-A).

    Techniques: Immunostaining, Control, Staining